TG THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
TG THERAPEUTICS, INC. (TGTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$8.12 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-27
- TG THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was -$8.12M.
- TG THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$1.60M.
- TG THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$10.62M, a 234.24% decline from fiscal 2022.
- TG THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $7.91M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$8.12M 10-K · filed 2026-02-27 | |
| 2024-12-31 | -$1.60M 10-K · filed 2026-02-27 | |
| 2023-12-31 | -$10.62M 10-K · filed 2026-02-27 | -$12.45M 10-K · filed 2024-02-29 |
| 2022-12-31 | $7.91M 10-K · filed 2025-03-03 | $17.60M 10-K · filed 2023-03-01 |
| 2021-12-31 | -$6.73M 10-K · filed 2024-02-29 | |
| 2020-12-31 | -$1.56K 10-K · filed 2023-03-01 | -$1.56M 10-K · filed 2021-03-01 |
| 2019-12-31 | $1.29K 10-K · filed 2022-03-01 | $1.29M 10-K · filed 2020-03-02 |
| 2018-12-31 | -$473.00 10-K · filed 2021-03-01 | $0.00 10-K · filed 2019-03-01 |
| 2017-12-31 | $8.21K 10-K · filed 2020-03-02 | $8.21M 10-K · filed 2018-03-15 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 | |
| 2015-12-31 | $0.00 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |